GE医疗科技（GEHC）周五盘中股价大涨5.04%，引发市场广泛关注。这一显著涨幅可能与该公司正在考虑的一项潜在收购有关。
据英国《金融时报》报道，强生支持的医疗技术公司HistoSonics正在探讨以超过25亿美元的估值出售。知情人士透露，GE医疗科技、美敦力和强生公司正在评估这项业务。HistoSonics公司开发了一种针对肝脏肿瘤的创新声波束疗法，这项技术可能会为收购方带来显著的市场机遇。
虽然交易尚未确定，但市场似乎对GE医疗科技可能扩大其医疗技术产品组合的前景反应积极。如果收购成功，这将有助于GE医疗科技在快速发展的医疗技术领域进一步巩固其地位。投资者将密切关注未来几周内可能出现的最终出价，以及这项潜在收购对GE医疗科技长期增长战略的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.